77 results about "Cardiovascular drug" patented technology

A system for developing and implementing empirically derived algorithms to generate decision rules to determine participant noncompliance and fraud with research protocols in clinical trials allows for the identification of complex patterns of variables that detect or predict participant noncompliance and fraud with research protocol, including performance and enrollment goals, in the clinical trial. The data may be used to overall predict the performance of any participant in a clinical trial, allowing selection of participants that tend to produce useful, high-quality results. The present invention can also be used to monitor participant compliance with the research protocol and goals to determine preferred actions to be performed. Optionally, the invention may provide a spectrum of noncompliance, from minor noncompliance needing only corrective feedback, to significant noncompliance requiring participant removal from the clinical trial or from future clinical trials. The algorithms and decision rules can also be domain-specific, such as detecting non-compliance or fraud among subjects in a cardiovascular drug trial, or demographically specific, such as taking into account gender, age or location, which provides for algorithms and decision rules to be optimized for the specific sample of participants being studied.

A process for preparing cardiovascular stent with a drug coating layer on its surface is disclosed. It includes the steps of: 1. pretreatment for the stent surface by plasma 2. dipping or spraying of the stent surface in routine method by hyperplasia proof drug and coating polymer containing solution The drug coated stent prepared by the present invention can endure long period washing by all kinds of stress and body fluid in the stent transportation and dilation process, with the coating layer not easy to falling off.

A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.

The invention discloses an application of maca imidazole alkaloid, in particular to an application to the preparation of cardiovascular drugs. All or part of the components are prepared from one or mixture of compounds having the following chemical structural formula as shown in formula (I), wherein R1 can be H or CH3, and R2 is H or OCH3. The invention first discovers the remarkable pharmaceutical activity of the compounds on blood pressure drop and arrhythmia resistance. Therefore, the maca imidazole alkaloid prepared by the new process can be used for developing antineoplastic drugs and can be expected to act as drugs for treating corresponding cardiovascular diseases. Formula (I).

The present invention discloses a rat myocardial cell separation culture method. According to the present invention, the myocardial cells being subjected to separation culture through the method have characteristics of high survival rate, complete myocardial cell and non-myocardial cell separation, rapid cell adherence, high purity, and early rhythmicity synchronized contraction time, and the method has characteristics of simple operation and good repeatability, is an ideal myocardial cell primary culture method, and can meet requirements of cardiovascular disease generation and development mechanisms, cardiovascular drug and cardiac tissue engineering researches, and a variety of physiological and biochemical experiments.

The invention discloses a method for constructing a blood capillary model and a microsystem chip thereof. The invention utilizes microsystem processing technology to design and manufacture a microchip system for ordered arrangement and culture of endothelial cells of a blood capillary. The method constructs the blood capillary model with normal physiological functions by the following three main steps: design and manufacture of the microsystem chip, transfer, arrangement, fixation and culture of the endothelial cells of the blood capillary, and measurement of the functions of the blood capillary model. The blood capillary model can be used for culturing and observing the endothelial cells of the blood capillary, can perform real-time measurement on the concentration of vasodilative factors NO excreted by the endothelial cells, can make the permeability of the tube wall changed along with different additional stimuli, approximately simulate the functions of the blood capillary under normal physiological conditions, and can be used for sieving active ingredients of cardiovascular drugs.

The invention provides an enhanced type fluorescent probe for detecting hydrogen sulfide. The fluorescent probe is an NRS fluorescent probe, the structural general formula of the NRS fluorescent probe is shown as (I), the preparation method comprises the following steps: adding nile red, 2,4-dinitrofluorobenzene and potassium carbonate into dimethylformamide, heating to 70-80DEG C, performing reflux reaction for 3 hours, extracting the reaction liquor by dichloromethane and collecting an organic phase, drying the organic phase with anhydrous magnesium sulfate, and purifying through silica column chromatography to obtain a target product. The probe has a mitochondrial location function, can perform real-time and on-site online detection to mitochondria, and can help us to further master the physiological function of the hydrogen sulfide and promote the understanding of physiological action of H2S, and provide a visible detection tool for research and development of novel cardiovascular drugs.

Representative embodiments of the present invention provide for novel, minimally invasive implantable devices and methods for targeted tissue drug delivery of cardiovascular drugs.

The invention discloses a synthesis method of 2-substituted-3, 4-dihyidro-1-isoquinoline ketone compound and a relative application in the drug preparation for cardiovascular disease, wherein the compound is represented as above, R1 is gaseous normal alkyl and aromatic group or various substituted alkyl and aromatic group of C1-C19, R2 is OH, OCH3, CH3, NO2 and halogen or the like and can be one or more substituents. The preparation of 2-substituted-3, 4-dihyidro-1-isoquinoline ketone compound uses isovanillic acid ester as raw material, via six-step reaction as allyl etherified, Claisen rearrangement, oxidation, reaction with primary amine (generating Schiff base), reduction and aminolysis of molecular lactone, to synthesize the product. The isolated arterial ring tension test proves that the compound can relax vessel effectively. The 2-substituted-3, 4-dihyidro-1-isoquinoline ketone compound is a new potential cardiovascular drug, with wide application for preparing the drug of cardiovascular disease.

A preparation method of a cardiovascular drug nilvadipine comprises the following steps of (1) cyclizing isopropyl 3-aminocrotonate, methyl 4,4-dimethoxyacetylacetate and m-nitrobenzaldehyde without a solvent or in an organic solvent I to obtain an intermediate compound I, (2) dissolving the compound I in an organic solvent II, adding 2-6 equivalents of acid, stirring for hydrolysis reaction for 1-12h to generate an intermediate compound II, (3) dissolving the intermediate compound II, 1.1-1.3 equivalents of hydroxylamine hydrochloride and 1.4-1.6 equivalents of alkali in the organic solvent III for reaction for 2.5-4h, adding water, stirring and filtering to obtain an intermediate compound III, and (4) dehydrating the compound III in an alkaline environment to obtain nilvadipine IV. The preparation method is simple in process, low in cost, can greatly improve the purity of a nilvadipine intermediate, and is suitable for large-scale industrial production, and the yield of nilvadipine is higher.

The invention provides a ziziphora clinopodioides Lam. total flavonoid extract and a production method thereof and the application thereof in cardiovascular drug. The ziziphora clinopodioides Lam. total flavonoid extract is obtained by the following method: extracting ziziphora clinopodioides Lam. dried crude drugs by using water or ethanol, absorbing by a macroporous resin column, decompressing, condensing and drying to obtain powdery dried aromatic ziziphora clinopodioides Lam. flavonoid extract with the color from yellow to claybank. The obtained extracts of ziziphora clinopodioides Lam. extract can be applied to the preparation of cardiovascular drugs, and can lower the yield (the taking dosage is reduced, the used crude drugs for reaching the same drug effect is reduced), thereby greatly saving ziziphora clinopodioides Lam. resources and reducing the cost while improving the healing effect.

A bioreactor and methods for use can include a microfibrous scaffold, that can be made of a composite bioink, and that can have endothelial cells directly embedded within the scaffold using an additive manufacturing process. The scaffold can further be seeded with cardiomyocytes. The hydrogel scaffold can be composed of a plurality of serpentine layers, with each serpentine layers, which can be placed on each other in a cross-hatch configuration, so that the primary axes of successive layers are perpendicular. This configuration can establish an aspect ratio for the scaffold, which can be selectively varied. For greater strength, the successive layers that have a primary axis in the same direction can be placed in the scaffold so that they are slight offset from each other. The scaffold can be placed in the bioreactor with perfusion, for use in cardiovascular drug screening and other nanomedicine endeavors.

The invention belongs to the technical field of medicine and relates to ziziphora bungeana dripping pills, a production method thereof and an application as a cardiovascular medicament. The ziziphora bungeana dripping pills are characterized by containing aromatic ziziphora bungeana total flavonoids and water-soluble pharmaceutical matrix, and the ratio of the water-soluble pharmaceutical matrix to the aromatic ziziphora bungeana total flavonoids in parts by weight is 1: 1 to 5: 1. The pharmacodynamic test result of the obtained ziziphora bungeana dripping pills shows that the ziziphora bungeana dripping pills have a protecting effect on myocardial ischemic injuries of rats, the anti-myocardial ischemia effect is greatly improved in comparison with the raw pharmaceutical material of the aromatic ziziphora bungeana total flavonoids, and the bioavailability and the clinical efficacy are improved. The obtained ziziphora bungeana dripping pills are convenient to use and good in patient compliance, and the production method is easy for industrialization.

The invention discloses an application of (Z)-2-imino-5-(3,5-dimethoxyphenylmethylene)-1-methylimidazolidinyl-4-one in the preparation of cardiovascular drugs. Specifically, the provided compound has a prominent effect on reducing damage caused by myocardial ischemia/reperfusion; is capable of prominently reducing the infarct volume in left ventricle of myocardial ischemia rats, and is suitable for preparing drugs for preventing and/or treating cardiovascular diseases especially ischemic cardiomyopathy, myocardial ischemia/reperfusion damage, and the like.

The invention discloses a method for preparing monacolin J. A lovastatin production bacterium Aspergillus terreus is used as an initial bacterium to prepare an important precursor monacolin J for synthesizing a cardiovascular drug simvastatin. The yield of the monacolin J is greater than 95%; compared with the monacolin J preparation technique reported at present, the invention does not use methanol or any other toxic solvent, and thus, satisfies the requirements of EHS (Environment, Health and Safety); the lovastatin fermentation mycelium serving as a raw material is treated to directly obtain the monacolin J without extracting the lovastatin pure product, thereby simplifying the technique, lowering the production cost and being applicable to industrial production.

The invention discloses a compound CYD19 which has a structure as shown a formula (I) which is described in the specification and is used as a Snail inhibitor or a pharmaceutically acceptable salt thereof, and a preparation method, a pharmaceutical composition and application of the compound CYD19 or the pharmaceutically acceptable salt thereof. The invention also discloses application of the compound in preparation of drugs for preventing or treating diseases with abnormal Snail expression. The invention especially relates to an application of the compound in preparation of antitumor and cardiovascular drugs. Pharmacological results show that the compound is highly compatible with Snail protein, and has good in-vitro anti-tumor cell proliferation effect, cell apoptosis promotion effect and tumor metastasis inhibition effect. The compound shows obvious in-vivo anti-tumor proliferation and metastasis activity in HCT-116 subcutaneous xenograft tumor nude mice and in-vivo liver metastasismodels of spleen injection, and is a potential drug clinically applicable to treatment of tumors.

The present disclosure describes a closed-loop fluid resuscitation and/or cardiovascular drug administration system that uses continuous measurements and adaptive control architecture. The adaptive control architecture uses a function approximator to identify unknown dynamics and physiological parameters of a patient to compute appropriate infusion rates and to regulate the endpoint of resuscitation.

The invention relates to an intermediate and method used for preparing dronedarone and belongs to the technical field of cardiovascular drugs. The method comprises the following steps of: using 2-n-butyl-5-acetamidobenzobfuran to react with p-anisoyl chloride under the catalysis of Lewis acid and obtain 2-n-butyl-3-(4-methoxy-benzoyl)-5-acetamidobenzobfuran; acidizing to obtain 2-n-butyl-3-(4-methoxy-benzoyl)-5-benzofuranamin hydrochloride, reacting with methylsulfonyl chloride to obtain 2-n-butyl-3-(4-methoxy-benzoyl)-5-methylsulfonylamidobenzobfuran; obtaining 2-n-butyl-3-(4-hydroxyl-benzoyl)-5-methylsulfonylamidobenzobfuran under the action of the Lewis acid; and reacting with 1,3-dibromopropane to obtain 2-n-butyl-3-[4-(gamma-bromopropyl)hydroxyl-benzoyl]-5-methylsulfonylamidobenzobfuran, and then reacting with di-n-butylamine to obtain dronedarone. The method avoids the catalytic hydrogenation reaction and has the advantages of available raw materials, simple operation process, high yield, easiness in industrialization and the like.

The invention belongs to the field of drug synthesis, and provides a ketanserin tartrate preparation method, wherein ketanserin and DL-tartaric acid are used as raw materials, ethanol is used as a solvent, heating dissolving is performed, and the target product is directly obtained through crystallization. According to the present invention, with the method, the total yield can reach 80%, and theproduct purity exceeds 99.0%; and the method has advantages of simple process synthesis steps, substantially reduced production cost and low environment pollution, and substantially alleviates the environmental problem caused by the production of ketanserin tartrate.

The invention provides compounds which are selective PDE2 inhibitors for use in the treatment of tachycardia or tachyarrhythmia Such compounds are particularly suitable for use in the treatment of any of the following conditions: atrial tachycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, premature ventricular contractions (PVCs), ventricular fibrillation and ventricular tachycardia, and may be used alone or in combination therapy with other conventional cardiovascular drugs, e.g. beta-blockers. In particular, the invention provides compounds which are selective PDE2 inhibitors for use in the treatment of ventricular tachycardia in patients who are suffering from, or who are at risk of suffering from heart failure, CPVT or long QT syndrome.